ExploreWatchlistsPricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Return on Assets

RIBOMIC Inc. (4591)

Market cap
¥3.5B
P/E ratio
-3.1x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on Assets (Million JPY)YoY (%)
Mar 31, 2025-30.3+20.17%
Mar 31, 2024-25.2-27.32%
Mar 31, 2023-34.7+13.90%
Mar 31, 2022-30.4+7.53%
Mar 31, 2021-28.3-19.92%
Mar 31, 2020-35.3+3.39%
Mar 31, 2019-34.2+9.45%
Mar 31, 2018-31.2+37.15%
Mar 31, 2017-22.8+132.58%
Mar 31, 2016-9.8

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat